EpiCept is an emerging specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses a deep and balanced pipeline of nine clinical product candidates, including:

• An oncology compound undergoing a Marketing Authorization Application (MAA) review in Europe.
• Three pain medications that are ready to enter, or have entered, Phase IIb or Phase III clinical trials.
• Three additional pain medications in Phase II trials.
• An oncology compound being prepared for Phase II trials for brain cancer and solid tumors.
• An apoptosis inducer for solid vascularized tumors entering Phase I trials.

EpiCept is headquartered in Tarrytown, New York. The Company’s R&D team in San Diego is pursuing oncology opportunities through a novel discovery platform that focuses on caspase-based apoptosis-inducing new chemical entities. EpiCept also possesses an in-house clinical research unit in Munich, Germany, which is managing the European clinical development of drug candidates.

EpiCept is listed on both the NASDAQ National Market and the OM Stockholm Exchange, under the symbol “EPCT”.